We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| KalVista Pharmaceuticals Inc | NASDAQ:KALV | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.04 | -0.33% | 12.13 | 9.99 | 12.35 | 12.48 | 11.955 | 12.24 | 199,657 | 21:35:11 |
From May 2019 to May 2024
PITTSBURGH, Jan. 19, 2017 /PRNewswire/ -- Law Office of Alfred G. Yates Jr., PC is investigating whether certain officers and directors of Carbylan Therapeutics, Inc. (NASDAQGM: CBYL) violated federal securities laws in connection with its initial public offering ("IPO"). Carbylan Therapeutics is a specialty pharmaceutical company that develops and commercializes novel and proprietary combination therapies.
On April 9, 2015, Carbylan's stock traded as high as $6.58, the same day the Company sold 13 million shares of stock in its initial public stock offering (the "IPO"), raising $65.0 million in new capital. However, since the IPO, Carbylan's stock has tumbled, falling from its high of $9.22 on June 8, 2015 to close at $0.49 on September 22, 2016.
On February 1, 2016 Carbylan stock plunged nearly 50 percent after the company disclosed top-line results from a Phase 3 trial, COR1.1. Then, in April 2016, Carbylan announced that it was suspending further clinical development of its pain relief product, Hydros–TA, and it is actively pursuing a merger or acquisition of the company. In concurrence, Carbylan also announced an immediate reduction in its workforce of 14 of its current 17 employees to preserve capital.
On May 12, 2016, the company reported net losses of approximately $6.6 million and $5.2 million in the three months ended March 31, 2016 and 2015, respectively.
As a result of a merger completed on November 22, 2016, Carbylan changed its name to KalVista Pharmaceuticals, Inc., an commenced trading under the symbol "KALV".
Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Alfred G. Yates Jr. at 1-800-391-5164, info@yatesclassactionlaw.com, or by the firm's website at yatesclassactionlaw.com.
Attorney Advertising. Past results do not guarantee a similar outcome.
Contact:
Alfred G. Yates Jr., Esquire
1-800-391-5164
info@yatesclassactionlaw.com
yatesclassactionlaw.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pittsburgh-law-office-of-alfred-g-yates-jr-pc-announces-investigation-of-carbylan-therapeutics-inc-cbyl-currently-known-as-kalvista-pharmaceuticals-inc-kalv-300393631.html
SOURCE Law Office of Alfred G. Yates Jr., PC
Copyright 2017 PR Newswire
1 Year KalVista Pharmaceuticals Chart |
1 Month KalVista Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
